
Review of Evolving Treatment Approaches in Pediatric Patients with Newly Diagnosed AML

References

1. Children's Oncology Group. *A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations.* clinicaltrials.gov; 2022. Accessed March 31, 2022. <https://clinicaltrials.gov/ct2/show/NCT04293562>
2. Pollard JA, Alonzo TA, Gerbing R, et al. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031 [published online ahead of print, 2022 Mar 29]. *J Clin Oncol.* 2022;JCO2101612. doi:10.1200/JCO.21.01612
3. Molica M, Perrone S, Mazzone C, et al. CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. *Cancers (Basel).* 2021;13(13):3214. Published 2021 Jun 28. doi:10.3390/cancers13133214
4. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. *Lancet Haematol.* 2021;8(7):e481-e491. doi:10.1016/S2352-3026(21)00134-4
5. Cooper TM, Absalon MJ, Alonzo TA, et al. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. *J Clin Oncol.* 2020;38(19):2170-2177. doi:10.1200/JCO.19.03306

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Jazz Pharmaceuticals.